The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Management of FL relapsed or progressed after frontline lenalidomide and rituximab
Loretta Nastoupil, MD, University of Texas MD Anderson Center, Houston, TX, discusses a retrospective study aiming to examine the treatment and outcome of follicular lymphoma (FL) patients who relapse and/or progress after an initial treatment with lenalidomide and rituximab (R2). Following relapse or progression, the patients received either chemoimmunotherapy or biological therapy. The median progression-free survival (PFS) was significantly longer in patients who received chemoimmunotherapy as compared to biological therapy at relapse. While these findings suggest that chemoimmunotherapy is an effective treatment strategy for patients with FL who relapse after frontline R2, the optimal salvage therapy for these patients needs to be further investigated. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
